The most severe iMCD subtype is the iMCD thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome, which involves systemic inflammation.[5] First-line treatment for iMCD syndrome includes glucocorticoids and IL-6 inhibitors; however, approximately 66% of patients with iMCD are IL-6 inhibitor-resistant.[6] Meanwhile, the treatment for recurrent cases has not yet been established. This evidence concerns the gene IL6 and Castleman-Kojima disease.